




Instance: composition-en-f556f9575aa3afd9667732b8d9b41fc4
InstanceOf: CompositionUvEpi
Title: "Composition for striascan Package Leaflet"
Description:  "Composition for striascan Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp173a30eedae0c48daf98b9e879ecfeee)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - striascan"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Striascan is and what it is used for  </li>
<li>What you need to know before Striascan is used </li>
<li>How Striascan is used </li>
<li>Possible side effects  </li>
<li>How Striascan is stored  </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What striascan is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What striascan is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>This medicine is a radiopharmaceutical product for diagnostic use only.  </p>
<p>Striascan contains the active substance ioflupane (123I) which is used to help identify (diagnose) conditions 
in the brain. It belongs to a group of medicines called  radiopharmaceuticals , which contain a small 
amount of radioactivity. 
* When a radiopharmaceutical is injected, it collects in a specific organ or area of the body for a 
short time. 
* Because it contains a small amount of radioactivity it can be detected from outside the body using 
special cameras. 
* A picture, known as a scan, can be taken. This scan will show exactly where the radioactivity is 
inside the organ and the body. This can give the doctor valuable information about how that organ 
is working. </p>
<p>Striascan is used only to identify illness. When this medicine is injected into a patient, it is carried around 
the body in the blood and collects in a small area of your brain. Changes in this area of the brain occur in: </p>
<ul>
<li>parkinsonism (including Parkinson s disease) and </li>
<li>dementia with Lewy bodies. </li>
</ul>
<p>A scan will give your doctor information about any changes in this area of your brain. Your doctor may 
feel that the scan would help in finding out more about your condition and deciding on possible treatment. </p>
<p>When Striascan is used, you are exposed to small amounts of radioactivity. This exposure is less than in 
some types of X-ray investigation. Your doctor and the nuclear medicine doctor have considered that the 
clinical benefit of this procedure with the radiopharmaceutical outweighs the risk of being exposed to 
these small amounts of radiation. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take striascan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take striascan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Striascan must not be used 
* if you are allergic to ioflupane or any of the other ingredients of this medicine (listed in section 6) 
* if you are pregnant. </p>
<p>Warnings and precautions 
Talk to your nuclear medicine doctor before using this medicine if you have moderate or severe 
problems with your kidneys or liver. </p>
<p>Before administration of Striascan you should drink plenty of water before the start of the examination 
in order to urinate as often as possible during the first hours after the study.   </p>
<p>Children and adolescents 
Striascan is not recommended for children and adolescents aged 0 to 18 years. </p>
<p>Other medicines and Striascan 
Tell your nuclear medicine doctor if you are taking or have recently taken any other medicines. 
Some medicines or substances can affect the way that this medicine works. 
These include: </p>
<ul>
<li>bupropion (used to treat depression (sadness)) </li>
<li>benzatropine (used to treat Parkinson s disease) </li>
<li>mazindol (reduces appetite, as a means to treat obesity) </li>
<li>sertraline (used to treat depression (sadness)) </li>
<li>methylphenidate (used to treat hyperactivity in children and narcolepsy (excessive sleepiness)) </li>
<li>phentermine (reduces appetite, as a means to treat obesity) </li>
<li>amfetamine (used to treat hyperactivity in children and narcolepsy (excessive sleepiness); also a 
drug of abuse) </li>
<li>cocaine (sometimes used as an anaesthetic for nose surgery; also a drug of abuse) </li>
</ul>
<p>Some medicines may reduce the quality of the picture obtained. The doctor may ask you to stop taking 
them for a short time before you receive Striascan. </p>
<p>Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your 
nuclear medicine doctor for advice before you are given this medicine. </p>
<p>You must inform the nuclear medicine doctor before the administration of Striascan if there is a 
possibility you might be pregnant, if you have missed your period or if you are breast-feeding.<br />
When in doubt, it is important to consult your nuclear medicine doctor who will supervise the procedure. </p>
<p>If you are pregnant, do not use Striascan. This is because the child may receive some of the 
radioactivity.  Alternative techniques which do not involve radioactivity should be considered. </p>
<p>If you are breast-feeding, your nuclear medicine doctor may delay the use of this product or ask you to 
stop breast-feeding. It is not known whether ioflupane (123I) you are given is passed into breast milk. 
* You should not breast-feed your child for 3 days after this product is given. 
* Instead use formula feed for your child. Express your breast milk regularly and throw away any 
breast milk you have expressed. 
* You will need to continue to do this for 3 days, until the radioactivity is no longer in your body. </p>
<p>Driving and using machines 
It is considered unlikely that Striascan will affect your ability to drive or to use machines. </p>
<p>Striascan contains alcohol (ethanol): up to 197 mg of alcohol in each dose which is equivalent to 39.5 
mg/mL (5% by volume). The amount in 5 mL of this medicine is equivalent to 5 mL beer or 2 mL wine. 
The small amount of alcohol in this medicine will not have any noticeable effects. </p>
<p>This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially  sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take striascan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take striascan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>There are strict laws on the use, handling and disposal of radioactivity. Striascan will always be used in a 
hospital or a similar place. It will only be handled and given to you by people who are trained and 
qualified to use it safely. They should tell you anything you need to do for the safe use of this medicine. 
The nuclear medicine doctor supervising the procedure will decide on the quantity of Striascan to be used 
in your case. It will be the smallest quantity necessary to get the desired information.<br />
The quantity to be administered usually recommended for an adult ranges from 110 to 185 MBq 
(megabecquerel or MBq, the unit used to measure radioactivity). </p>
<p>Administration of Striascan and conduct of the procedure 
Before you receive Striascan, your nuclear medicine doctor will ask you to take some tablets or liquid that 
contain iodine. These stop the radioactivity building-up in your thyroid gland. It is important that you take 
the tablets or liquid as the doctor tells you. </p>
<p>Striascan is given to you as an injection, usually into a vein in your arm. A single injection is enough.  </p>
<p>Duration of the procedure<br />
The camera pictures are usually taken 3 to 6 hours after the injection of this product. Your nuclear 
medicine doctor will inform you about the usual duration of the procedure. </p>
<p>After administration of Striascan, you should urinate frequently in order to eliminate the product from 
your body.  </p>
<p>The nuclear medicine doctor will inform you if you need to take any special precautions after receiving 
this medicine. Contact your nuclear medicine doctor if you have any questions. </p>
<p>If you are given more Striascan than you should 
Since this product is given by a doctor under controlled conditions, it is unlikely that you will get an 
overdose. Your nuclear medicine doctor will suggest that you drink plenty of fluids to help the body get 
rid of the medicine. You will need to be careful with the water (urine) that you pass - your doctor will tell 
you what to do. This is normal practice with medicines like Striascan. Any ioflupane (123I) which remains 
in your body will naturally lose its radioactivity. </p>
<p>If you have any further questions on the use of this medicine, ask your nuclear medicine doctor who 
supervises the procedure. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. 
The frequency of side effects is: 
Common: may affect up to 1 in 10 people 
- Headache </p>
<p>Uncommon: may affect up to 1 in 100 people 
- Increased appetite 
- Dizziness 
- Taste disturbance 
- Nausea 
- Dry mouth 
- Vertigo 
- A brief irritating feeling similar to ants crawling over your skin (formication) 
- Intense pain (or burning sensation) at the injection site. This has been reported among patients 
receiving this product into a small vein. </p>
<p>Not known: frequency cannot be estimated from the available data. 
- Hypersensitivity (allergic) 
- Shortness of breath 
- Redness of the skin 
- Itching 
- Rash 
- Hives (urticaria) 
- Excessive sweating 
- Vomiting 
- Low blood pressure 
- Feeling hot. </p>
<p>This radiopharmaceutical will deliver low amounts of ionising radiation associated with the least risk of 
cancer and hereditary abnormalities.  </p>
<p>Reporting of side effects 
If you get any side effects, talk to your nuclear medicine doctor. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system listed in 
Appendix V.<br />
By reporting side effects you can help provide more information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store striascan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store striascan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>You will not have to store this medicine. This medicine is stored under the responsibility of the specialist 
in appropriate premises. Storage of radiopharmaceuticals will be in accordance with national regulation 
on radioactive materials. </p>
<p>The following information is intended for the specialist only: 
* Do not store above 25 C. 
* Do not freeze. </p>
<p>Do not use this medicine after the expiry date which is stated on the labels after EXP. Hospital staff will 
ensure that the product is stored and thrown away correctly and not used after the expiry date stated on 
the label. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Striascan contains<br />
- The active substance is ioflupane (123I).<br />
Each mL of solution contains 74 MBq of ioflupane (123I) at reference time. </p>
<ul>
<li>The other ingredients are acetic acid, glacial (E 260); sodium acetate trihydrate (E 262); ethanol, 
anhydrous (E 1510); phosphoric acid, concentrated (E 338) and water for injections. </li>
</ul>
<p>What Striascan looks like and contents of the pack 
Striascan is a colourless solution for injection, supplied in a single amber 15 mL glass vial sealed with a 
rubber closure and metal overseal. </p>
<p>Pack size: 1 vial containing 2.5 mL or 5 mL. </p>
<p>Marketing Authorisation Holder and Manufacturer </p>
<p>CIS bio international 
RN 306   Saclay 
B.P. F-91192 Gif-sur-Yvette Cedex 
FRANCE </p>
<p>This leaflet was last revised in {MM/YYYY}. </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site:  </p>         </div>"""      



Instance: composition-da-f556f9575aa3afd9667732b8d9b41fc4
InstanceOf: CompositionUvEpi
Title: "Composition for striascan Package Leaflet"
Description:  "Composition for striascan Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp173a30eedae0c48daf98b9e879ecfeee)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - striascan"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse<br />
2. Det skal De vide, før De begynder at bruge Striascan 
3. Sådan skal De Striascan bruge 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What striascan is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What striascan is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel er et radioaktivt præparat, der kun er beregnet til diagnostisk brug. </p>
<p>Striascan indeholder det aktive stof ioflupan (123I), der anvendes som hjælp til at identificere 
(diagnosticere) sygdomme i hjernen. Det tilhører en gruppe lægemidler, der kaldes "radioaktive 
lægemidler", som indeholder en lille mængde radioaktivitet.  </p>
<ul>
<li>
<p>Når et radioaktivt lægemiddel injiceres, samler det sig sammen i et specifikt organ eller 
bestemte dele af kroppen i kort tid.  </p>
</li>
<li>
<p>Da det indeholder en lille mængde radioaktivitet, kan det påvises udefra ved anvendelse af 
specielle kameraer.  </p>
</li>
<li>
<p>Der kan tages et billede, der kaldes en scanning. Dette scanningsbillede vil vise præcist, hvor 
radioaktiviteten befinder sig i organet eller i kroppen. Dette kan give lægen værdifuld 
information om, hvordan organet fungerer.  </p>
</li>
</ul>
<p>Striascan bruges kun til at identificere sygdom. Efter indsprøjtning fordeles lægemidlet i kroppen via 
blodet og samler sig i små områder af hjernen. Forandringer i denne del af hjernen forekommer ved:  </p>
<ul>
<li>
<p>parkinsonisme (herunder Parkinsons sygdom) og  </p>
</li>
<li>
<p>Lewy-body-demens  </p>
</li>
</ul>
<p>En scanning vil give Deres læge information om enhver forandring i dette område af Deres hjerne. 
Deres læge kan vurdere, at scanningen kan bidrage til at finde ud af mere om Deres tilstand og til at 
træffe beslutning om mulig behandling.  </p>
<p>Når De får Striascan, eksponeres De for en lille mængde radioaktivitet. Denne eksponering er mindre 
end under visse former for røntgenundersøgelser. Deres læge og den nuklearmedicinske læge har 
vurderet, at de kliniske fordele ved denne undersøgelse med det radioaktive lægemiddel, overstiger 
risikoen ved at blive udsat for disse små mængder stråling. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take striascan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take striascan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug ikke Striascan:</p>
<ul>
<li>hvis De er allergisk over for ioflupan eller et af de øvrige indholdsstoffer i Striascan (angivet i 
afsnit 6).  </li>
<li>hvis De er gravid.  </li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt den nuklearmedicinske læge, før De bruger dette lægemiddel, hvis De har moderate eller 
svære problemer med nyrer eller lever. </p>
<p>Før indgivelse af Striascan bør De drikke masser af vand inden undersøgelsens start, så De kan lade 
vandet så ofte som muligt i de første timer efter undersøgelsen. </p>
<p>Børn og unge 
Striascan anbefales ikke til børn og unge i alderen 0 til 18 år. </p>
<p>Brug af anden medicin sammen med Striascan </p>
<p>Fortæl det altid til den nuklearmedicinske læge, hvis De bruger anden medicin eller har gjort det for 
nylig. Nogle lægemidler og præparater kan påvirke den måde, dette lægemiddel virker på.<br />
De omfatter:  </p>
<ul>
<li>
<p>bupropion (anvendes til at behandle depression (nedtrykthed))  </p>
</li>
<li>
<p>benzatropin (anvendes til at behandle Parkinsons sygdom)  </p>
</li>
<li>
<p>mazindol (nedsætter appetitten, et middel til at behandle fedme)  </p>
</li>
<li>
<p>sertralin (anvendes til at behandle depression (nedtrykthed))  </p>
</li>
<li>
<p>methylphenidat (anvendes til at behandle hyperaktivitet hos børn og narkolepsi (overdreven 
søvnighed))  </p>
</li>
<li>
<p>phentermin (nedsætter appetitten, et middel til at behandle fedme)  </p>
</li>
<li>
<p>amfetamin (anvendes til at behandle hyperaktivitet hos børn og narkolepsi (overdreven 
søvnighed); også et misbrugsstof)  </p>
</li>
<li>
<p>cocain (anvendes til tider som et anæstetikum ved næsekirurgi; også et misbrugsstof)  </p>
</li>
</ul>
<p>Visse lægemidler kan reducere den opnåede billedkvalitet. Lægen vil eventuelt bede Dem om at holde 
op med at tage dem i en kort periode, inden De får Striascan. </p>
<p>Graviditet og amning<br />
Hvis De er gravid eller ammer, har mistanke om, at De er gravid, eller planlægger at blive 
gravid, skal De spørge den nuklearmedicinske læge til råds, før De får dette lægemiddel. </p>
<p>De skal informere den nuklearmedicinske læge inden indgivelse af Striascan, hvis der er en mulighed 
for, at De kan være gravid, hvis en menstruation er udeblevet, eller hvis De ammer. Hvis De er i tvivl, 
er det vigtigt, at De spørger den nuklearmedicinske læge, som skal overvåge undersøgelsen, til råds. </p>
<p>Hvis De er gravid, brug ikke Striascan. Barnet kan få tilført noget af radioaktiviteten. Andre 
teknikker, som ikke involverer radioaktivitet, skal overvejes.  </p>
<p>Hvis De ammer, kan den nuklearmedicinske læge eventuelt udsætte anvendelsen af dette lægemiddel 
eller bede Dem om at ophøre med at amme. Det vides ikke, om det ioflupan (123I), De får, går over i 
brystmælken.  </p>
<ul>
<li>
<p>De bør ikke amme Deres barn de første 3 dage efter, at du har fået dette lægemiddel.  </p>
</li>
<li>
<p>Brug i stedet modermælkserstatning til barnet. Malk regelmæssigt brystmælken ud, og kasser al 
den udmalkede mælk.  </p>
</li>
<li>
<p>De skal fortsætte med at gøre dette i 3 dage, indtil der ikke længere er radioaktivitet tilbage i 
kroppen.  </p>
</li>
</ul>
<p>Trafik- og arbejdssikkerhed 
Det er ikke sandsynligt, at Striascan vil påvirke Deres evne til at føre motorkøretøj eller betjene 
maskiner. </p>
<p>Striascan indeholder alkohol (ethanol): op til 197 mg alkohol i hver dosis, svarende til 39,5 mg/ml 
(5 volumen%). Mængden i 5 ml af lægemidlet svarer til 5 ml øl eller 2 ml vin. Den lille mængde 
alkohol, der er i dette lægemiddel, vil ikke have nogen mærkbar effekt. </p>
<p>Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. hætteglas, dvs. det er i det 
væsentlige natrium-frit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take striascan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take striascan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Der er streng lovgivning om anvendelse, håndtering og bortskaffelse af radioaktivitet. Striascan vil 
altid blive anvendt på et hospital eller et lignende sted. Det vil kun blive håndteret og givet til Dem af 
personer med træning og kvalifikationer i at anvende det sikkert. De vil fortælle Dem alt, hvad De skal 
gøre med henblik på sikker brug af denne medicin. </p>
<p>Den nuklearmedicinske læge, der overvåger undersøgelsen, afgør hvilken mængde Striascan, der skal 
bruges i undersøgelsen af Dem. Det vil være den mindst mulige mængde, der er nødvendig for at få 
den ønskede information. 
Den mængde, der sædvanligvis anbefales indgivet til en voksen, ligger i intervallet fra 110 til 
185 MBq (megabequerel eller MBq, som er den enhed, der anvendes til at udtrykke radioaktivitet). </p>
<p>Indgivelse af Striascan og undersøgelsens udførelse 
Før De får Striascan, vil Deres nuklearmedicinske læge bede Dem om at tage tabletter eller væske, der 
indeholder jod. Det vil forhindre ophobning af radioaktivitet i Deres skjoldbruskkirtel. Det er vigtigt, 
at De tager tabletterne eller væsken i henhold til lægens anvisninger.  </p>
<p>De vil få Striascan som en injektion, sædvanligvis i en blodåre i armen. En enkelt injektion er nok.  </p>
<p>Undersøgelsens varighed 
Kamerabillederne bliver normalt taget 3 til 6 timer efter injektionen af dette lægemiddel. Den 
nuklearmedicinske læge vil informere Dem om, hvor længe undersøgelsen sædvanligvis varer. </p>
<p>Efter indgivelse af Striascan skal De lade vandet hyppigt, så lægemidlet kan komme ud af kroppen. </p>
<p>Den nuklearmedicinske læge vil informere Dem, hvis De skal tage nogen særlige forholdsregler, efter 
at De har fået dette lægemiddel. Kontakt den nuklearmedicinske læge, hvis De har nogen spørgsmål. </p>
<p>Hvis De har fået for meget Striascan<br />
Eftersom dette lægemiddel gives af en læge under kontrollerede forhold, er det usandsynligt, at De vil 
få en overdosis. Deres nuklearmedicinske læge vil foreslå, at De drikker meget væske for at hjælpe 
kroppen med at slippe af med medicinen. De skal være påpasselig med den urin, som De udskiller i 
forbindelse med vandladning – Deres læge vil fortælle Dem, hvad De skal gøre. Dette er normal 
praksis for lægemidler som Striascan. Det ioflupan (123I), som forbliver i Deres krop, vil naturligt 
miste dets radioaktivitet.  </p>
<p>Spørg den nuklearmedicinske læge, der overvåger undersøgelsen, hvis der er noget, De er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger.<br />
Hyppigheden af bivirkninger er: </p>
<p>Almindelig: kan forekomme hos op til 1 ud af 10 behandlede<br />
- Hovedpine  </p>
<p>Ikke almindelig: kan forekomme hos op til 1 ud af 100 behandlede<br />
- Øget appetit<br />
- Svimmelhed<br />
- Smagsforstyrrelser<br />
- Kvalme<br />
- Mundtørhed<br />
- Svimmelhed<br />
- En let irriterende følelse af, at der er myrer, der kravler på Deres hud (myrekryb)<br />
- Intens smerte (eller brændende fornemmelse) ved injektionsstedet. Dette er blevet rapporteret 
hos patienter, der fik dette lægemiddel i en lille blodåre. </p>
<p>Ikke kendt: hyppigheden kan ikke estimeres ud fra forhåndenværende data.<br />
- Overfølsomhed (allergi)<br />
- Åndenød<br />
- Rødme af huden<br />
- Kløe<br />
- Udslæt<br />
- Nældefeber (urticaria)<br />
- Øget svedtendens<br />
- Opkastning<br />
- Lavt blodtryk 
- Varmefølelse  </p>
<p>Dette radioaktive præparat afgiver lave mængder ioniserende stråling, der forbindes med den laveste 
risiko for cancer og arvelige abnormiteter. </p>
<p>Indberetning af bivirkninger 
Hvis De oplever bivirkninger, bør De tale med Deres nuklearmedicinske læge, sygeplejerske eller 
apoteket. Dette gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. De<br />
eller Deres pårørende kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det 
nationale rapporteringssystem anført i Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe 
med at fremskaffe mere information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store striascan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store striascan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>De skal ikke opbevare dette lægemiddel. Dette lægemiddel opbevares på en dertil bestemt lokalitet 
under ansvar af specialisten. Opbevaring af radioaktive lægemidler foregår i henhold til nationale 
bestemmelser vedrørende radioaktive materialer.  </p>
<p>Følgende information er udelukkende beregnet for specialisten:  </p>
<ul>
<li>
<p>Må ikke opbevares ved temperaturer over 25 °C.  </p>
</li>
<li>
<p>Må ikke nedfryses.  </p>
</li>
</ul>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på etiketterne efter Exp. Hospitalets personale 
sørger for, at produktet opbevares og bortskaffes korrekt og ikke anvendes efter udløbsdatoen angivet 
på etiketten. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Striascan indeholder:</p>
<ul>
<li>
<p>Aktivt stof: ioflupan (123I).<br />
Hver ml opløsning indeholder 74 MBq ioflupan (123I) på referencetidspunktet.  </p>
</li>
<li>
<p>Øvrige indholdsstoffer: eddikesyre, koncentreret (E260); natriumacetat trihydrat (E262); ethanol 
vandfri (E1510); phosphorsyre koncentreret (E338) og vand til injektionsvæsker.  </p>
</li>
</ul>
<p>Udseende og pakningstørrelse 
Striascan er en farveløs injektionsvæske, opløsning, der leveres i ét enkelt ravgult 15 ml hætteglas 
forseglet med et gummilukke og metalforsegling. </p>
<p>Pakningsstørrelse: 1 hætteglas med 2,5 ml eller 5 ml. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller </p>
<p>CIS bio international 
RN 306 – Saclay 
B.P. F-91192 Gif-sur-Yvette Cedex 
FRANKRIG </p>
<p>Denne indlægsseddel blev senest ændret MM/ÅÅÅÅ </p>
<p>De kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>
<p>Denne indlægsseddel findes på alle EU-/EØS-sprog på Det Europæiske Lægemiddelagenturs 
hjemmeside. 
------------------------------------------------------------------------------------------------------------------------ Nedenstående oplysninger er til læger og sundhedspersonale: </p>
<p>Det fuldstændige produktresumé for Striascan er indlagt som et separat dokument i pakningen med det 
formål at give sundhedspersonalet yderligere videnskabelig og praktisk information om administration 
og brug af dette radioaktive præparat. 
Der henvises til produktresuméet. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-f556f9575aa3afd9667732b8d9b41fc4
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for striascan Package Leaflet for language en"
Description: "ePI document Bundle for striascan Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-f556f9575aa3afd9667732b8d9b41fc4"
* entry[0].resource = composition-en-f556f9575aa3afd9667732b8d9b41fc4

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpf556f9575aa3afd9667732b8d9b41fc4"
* entry[=].resource = mpf556f9575aa3afd9667732b8d9b41fc4
                            
                    
Instance: bundlepackageleaflet-da-f556f9575aa3afd9667732b8d9b41fc4
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for striascan Package Leaflet for language da"
Description: "ePI document Bundle for striascan Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-f556f9575aa3afd9667732b8d9b41fc4"
* entry[0].resource = composition-da-f556f9575aa3afd9667732b8d9b41fc4

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpf556f9575aa3afd9667732b8d9b41fc4"
* entry[=].resource = mpf556f9575aa3afd9667732b8d9b41fc4
                            
                    



Instance: mpf556f9575aa3afd9667732b8d9b41fc4
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product striascan"
Description: "striascan"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/19/1372/001 (2.5 mL)"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "This medicinal product is for diagnostic use only."


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "striascan"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: f556f9575aa3afd9667732b8d9b41fc4ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "striascan"

* status = #current
* mode = #working

* title = "List of all ePIs associated with striascan"

* subject = Reference(mp173a30eedae0c48daf98b9e879ecfeee)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#striascan "striascan"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-f556f9575aa3afd9667732b8d9b41fc4) // striascan en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-f556f9575aa3afd9667732b8d9b41fc4) // striascan da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-f556f9575aa3afd9667732b8d9b41fc4
InstanceOf: List

* insert f556f9575aa3afd9667732b8d9b41fc4ListRuleset
    